Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Social Support in Relation to Fatigue Symptoms Among Patients with Multiple Sclerosis.
FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.
Dimethyl fumarate protection against collagen II degradation.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
Clinically isolated syndromes.
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Neuro-Immune Interactions at Barrier Surfaces.
Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Multiple sclerosis review.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Glatiramer acetate induced hepatotoxicity.
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.
Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Trimesta (Oral Estriol)
Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient.
Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells.
Myelin in cartilaginous fish.
Pages
« first
‹ previous
…
39
40
41
42
43
44
45
46
47
…
next ›
last »